Re-release of Drug Watch guidance
FDA expects to release its revised Drug Watch guidance "very soon," according to CDER Director Steven Galson. "We're very close to completing the guidance that responds to the initial draft we put out and comes up with decisions on each of those questions that were raised," Galson says Sept. 22. The original plans for a website for posting emerging risk information drew intense criticism, prompting FDA to redraft the guidance (1"The Pink Sheet" Feb. 21, 2006, p. 5)...
You may also be interested in...
FDA's Drug Safety Oversight Board should start shifting its focus toward broader policy questions - like standards for boxed warnings - in addition to addressing emerging safety issues for specific products, DSOB Executive Director Susan Cummins suggested
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.